Mineralys Therapeutics, Inc. $MLYS Shares Sold by ADAR1 Capital Management LLC

Key Takeaways:

• ADAR1 Capital reduced its stake in Mineralys Therapeutics by 68.7%.
• It sold 578,116 shares, retaining 263,425 by the end of the first quarter.
• The remaining position is valued at $4,183,000.
• These figures were reported by Holdings Channel.
• The announcement was published on 2025-09-02.

Introduction

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) made headlines when ADAR1 Capital Management LLC significantly reduced its holdings earlier this year. The financial investment firm, known for its strategic moves within the pharmaceutical and biotech sectors, decided to cut back on the number of shares it holds in Mineralys by a substantial margin.

Details of the Stake Reduction

In the first quarter of the year, ADAR1 Capital slashed its stake by 68.7%, selling 578,116 shares. Following this divestment, the institutional investor maintained 263,425 shares of Mineralys Therapeutics. This data, obtained through a filing accessed via Holdings Channel, highlights how swiftly investment firms can shift their portfolios in response to market trends and their own internal strategies.

Financial Worth of Remaining Shares

Despite the reduced position, ADAR1 Capital’s remaining shares still command a notable presence in Mineralys. The firm’s 263,425 shares were valued at approximately $4,183,000 by the end of the period surveyed. While the exact reasons behind the reduction remain undisclosed in the filing, the figures underscore the continuing confidence, albeit scaled back, in the company’s potential.

Conclusion

This significant sell-off by a high-profile institutional investor demonstrates the fluid nature of financial and investment dynamics. As reported by Daily Political on September 2, 2025, ADAR1 Capital’s revised stake in Mineralys Therapeutics, Inc. sheds light on the ever-evolving strategies of major market players.